Literature DB >> 11183899

The prevalence of overactive bladder.

I Milsom, W Stewart, J Thüroff.   

Abstract

Overactive bladder (OAB) is a disorder that encompasses frequency, urgency, and urge incontinence, singly or in combination. It often has a significant individual impact on quality of life and on limitations to activities, yet most individuals with OAB do not seek medical care. Therefore, it is not possible to estimate the prevalence and, more generally, the societal impact of OAB based on medical encounter data. With few exceptions, most epidemiologic studies have focused on urge incontinence, the most severe form of OAB. The prevalence of OAB increases with age and is more common in women than men. However, prevalence estimates vary considerably among studies, ranging from 3% to 43%. The variation in estimates from epidemiologic studies is the result in part of differences in the criteria used to define a case of urge incontinence among studies. This problem is attributable in part to the lack of a standardized, validated, and operational definition. Nonetheless, consensus exists regarding the significant individual and societal impact of urge incontinence and the recognition that it is underdiagnosed and undertreated. Frequency and urgency, the other 2 symptoms of OAB, have not received the same level of attention as urge incontinence, yet the societal impact of these symptoms of OAB may be considerably greater. Overall, frequency and urgency are considerably more common symptoms than urge incontinence, especially between 35 and 55 years of age, the period of peak productivity for most workers. Recent evidence indicates that a substantial proportion of individuals with frequency and urgency report a diminished quality of life and interference with activities in a number of roles, including work. Efforts are under way to more accurately describe the prevalence of frequency and urgency, using a validated and standardized epidemiologic case definition to determine the individual impact of each symptom of OAB and to estimate societal costs.

Entities:  

Mesh:

Year:  2000        PMID: 11183899

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  26 in total

1.  Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.

Authors:  Linda Cardozo; David Castro-Diaz; Marc Gittelman; Arwin Ridder; Moses Huang
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-04-20

2.  Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.

Authors:  Rodney U Anderson; Scott MacDiarmid; Sherron Kell; James H Barada; Scott Serels; Roger P Goldberg
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-05-03

Review 3.  Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.

Authors:  Scott Martin Vouri; Clark D Kebodeaux; Paul M Stranges; Besu F Teshome
Journal:  Arch Gerontol Geriatr       Date:  2016-11-14       Impact factor: 3.250

4.  Urge incontinence: estimating environmental and obstetrical risk factors using an identical twin study.

Authors:  Tondalaya L Gamble; Hongyan Du; Peter K Sand; Sylvia M Botros; Magdalena Rurak; Roger P Goldberg
Journal:  Int Urogynecol J       Date:  2010-05-06       Impact factor: 2.894

5.  The Aging Overactive Bladder: A Review of Aging-Related Changes from the Brain to the Bladder.

Authors:  Anne M Suskind
Journal:  Curr Bladder Dysfunct Rep       Date:  2017-02-06

6.  Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment.

Authors:  Scott Martin Vouri; Mario Schootman; Seth A Strope; Stanley J Birge; Margaret A Olsen
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

7.  Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

8.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.

Authors:  M-S Choo; J Z Lee; J B Lee; Y-H Kim; H C Jung; K-S Lee; J C Kim; J T Seo; J-S Paick; H-J Kim; Y G Na; J G Lee
Journal:  Int J Clin Pract       Date:  2008-11       Impact factor: 2.503

10.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.